propel: analysis of drug interactions between olaparib abiraterone as 1l therapy in mcrpc
Published 2 years ago • 136 plays • Length 0:51Download video MP4
Download video MP3
Similar videos
-
1:45
the propel clinical trial exploring olaparib plus abiraterone in mcrpc
-
3:07
propel: olaparib plus abiraterone as 1l treatment for metastatic crpc
-
0:44
propel: gene-by-gene efficacy of olaparib and abiraterone in mcrpc
-
5:36
propel trial
-
4:08
propel: final os of first-line abiraterone plus olaparib for mcrpc
-
4:25
phase 3 magnitude study
-
22:00
how i live with stage 4 metastatic prostate cancer | mark's story | the patient story
-
3:08
a human-in-the-loop drug discovery platform integrating humans, ai, and robots
-
1:27
hrqol and pain outcomes in mcrpc: abi ala vs abi pbo in propel
-
3:41
olaparib plus abiraterone could be a new first-line treatment option for mcrpc | fred saad
-
4:56
fred saad, esmo 2022: phase iii propel trial of abiraterone olaparib in prostate cancer
-
1:19
highlights in prostate cancer from esmo
-
5:20
add-on parp inhibition in metastatic crpc: propel and magnitude | david vanderweele
-
3:30
2020 in review: olaparib & rucaparib, fda approval | ask a prostate expert, mark scholz, md
-
5:14
olaparib and keytruda for advanced prostate cancer | | learn about clinical trials
-
0:49
unmet needs for patients with prostate cancer
-
1:37
recent advances in mhspc: 177lu-psma-617, propel and biomarker-directed strategies
-
0:30
prostate cancer treatment with proton therapy (advantages) at procure, new jersey
-
1:39
challenges in the field of parpi treatment for mcrpc
-
0:39
talapro-2: rpfs and os of talazoparib and enzalutamide in mcrpc
-
1:21
combining a parp and pd-l1 inhibitor to treat prostate cancer
-
1:15
exciting times for hormone-sensitive prostate cancer treatment